The GLP-1RA Pipeline is Full - Here's What to Expect
There are lots of products in development for weight loss and to treat other metabolic diseases which means more options for more people.
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Death in Persons with CKD, T2D: Daily Dose
Your daily dose of the clinical news you may have missed.
GLP-1RAs, SGLT-2 Inhibitors Tied to Lower Adverse Cardiovascular and Liver Events in Persons with T2D, MASLD
ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.
BMI is Still a Reliable Screening Tool for Youth with Elevated Adiposity, Study Affirms
Despite its limitations for use in other populations, a high BMI proved a very good predictor of dangerous fat mass index in youth aged 8 to 19 years in this study.
Premenstrual Disorders Increase Suicide Risk: Daily Dose
Endocrine Society Releases New Clinical Guideline on Vitamin D Supplementation for Prevention of Disease
ENDO 2024. The expert panel suggests children, pregnant persons, adults aged ≥75 years, and adults with prediabetes consume more vitamin D than the recommended daily allowance.
Ultraprocessed Foods Raise Risk for Cardiometabolic Issues in Children: Daily Dose
FDA Grants EUA for OTC Triple Test for COVID-19, Flu A & B
The over-the-counter antigen test, for use at home or at point of care, discriminates between SARS-CoV-2 and influenza A and B in 15 minutes.
FDA Approves Moderna's mRESVIA, First mRNA Vaccine Against RSV, for Adults Aged ≥60 Years
mRESVIA is Moderna's second mRNA-based vaccine and will be shipped in prefilled syringes, a desirable feature that could save clinical time, prevent errors.
New Online Tracker May Help Patients Find GLP-1RA Medication More Easily
The interactive tool provides clinicians and patients a real-time look at GLP-1RA availability.
Surya Bhatt, MD, MSPH, Reports the Pivotal Phase 3 Findings for Dupilumab as Add-On Treatment for COPD
The dual interleukin-4, 13 inhibitor reduced COPD exacerbation rates by as much as 34% for individuals with COPD with type 2 inflammation, Bhatt explains.
FDA Decision on Dupilumab for COPD Pushed Back to September 2024
FDA has no concerns about the "approvability" of dupilumab for the new indication but needs additional time to review phase 3 data it requested early in May.
COVID-19 Infection in Second Trimester Raises Risk of Preeclampsia: Daily Dose
Primary Care Needs Training on Menopausal Issues, Treatment Options, says Women's Midlife Health Expert
Primary care clinicians are essential to maximizing evidence-based midlife care for women, according to Professor of Obstetrics & Gynecology JoAnn Pinkerton, MD.
Semaglutide Explored for Treatment of Alcohol, Nicotine Use Disorders
Findings from 2 early stage studies reported at a recent clinical meeting support the safety and tolerability of the GLP-1RA in persons with substance use disorders.
Premenstrual Disorders May Increase Suicide Risk, Especially Among Young Women, Study Warns
The risk of mortality was not higher for women with vs without PMD overall but was particularly elevated for young women and for suicide across age of PMD diagnosis.
Elinzanetant Outcomes from the OASIS 1 and 2 Phase 3 Trials: A Read Out with Lead Investigator JoAnn Pinkerton, MD
The novel dual neurokinin-1,3 antagonist reduced VMS after just 1 week of treatment, Pinkerton said, and improved sleep and quality of life, as well. Hear more.
Women's Preventive Services Guideline: 7 Questions
These 7 questions are based on the most recent update to the guidelines by the Women's Preventive Services Initiative, including supporting resources.
Plozasiran, an Investigational RNAi Therapy, Reduces Triglyceride Levels in Adults with Mixed Hyperlipidemia
Plozasiran, in the phase 2b MUIR trial, significantly reduced triglyceride and triglyceride rich lipoprotein levels through targeted action against APOC3.
Tezepelumab Found to Reduce Rate of COPD Exacerbations in Persons with Wide Range of Blood Eosinophil Levels: Daily Dose